You are here: Industry Insights > Shenogen

News List

Shenogen enters into an exclusive license with BioArdis to develop and commercialise FGFR4 kinase inhibitor for Asian market pharmaceutical-business-review
April 08, 2020
Shenogen has entered into an exclusive collaboration and licensing agreement with Shanghai BioArdis and BioArdis for the development and commercialization of BioArdis' novel FGFR4 ...
Innovent and Shenogen study Tyvyt-SNG1005 combination for cancer pharmaceutical-technology
August 07, 2019
Innovent Biologics and Shenogen Pharma Group have signed a collaboration agreement to evaluate the combination therapy of Innovent’s Tyvyt with Shenogen’s SNG1005, in patients with advanced cancer.
Innovent and Shenogen Announce Collaboration to Evaluate Tyvyt® (Sintilimab injection) in Combination with SNG1005 for the Treatment of Patients with Advanced Cancer prnasia
August 06, 2019
Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines, today announced the signing of a collaboration agreement with ...